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Abstract: Ever since the hypothesis was put forward that estrogens could protect against 
cerebral ischemia, numerous studies have investigated  the mechanisms of their  effects. 
Despite initial studies showing ameliorating effects, later trials in both humans and animals 
have yielded contrasting results regarding the fundamental issue of whether estrogens are 
neuroprotective or neurodamaging. Therefore, investigations of the possible mechanisms 
of estrogen actions in brain ischemia have been difficult to assess. A recently published 
systematic review from our laboratory indicates that the dichotomy in experimental rat 
studies  may  be  caused  by  the  use  of  insufficiently  validated  estrogen  administration 
methods  resulting  in  serum  hormone  concentrations  far  from  those  intended,  and  that 
physiological  estrogen  concentrations  are  neuroprotective  while  supraphysiological 
concentrations augment the damage from cerebral ischemia. This evidence offers a new 
perspective on the mechanisms of estrogens’ actions in cerebral ischemia, and also has a 
direct bearing on the hormone replacement therapy debate. Estrogens affect their target 
organs by several different pathways and receptors, and the mechanisms proposed for their 
effects on stroke probably prevail in different concentration ranges. In the current article, 
previously suggested neuroprotective and neurodamaging mechanisms are reviewed in a 
hormone concentration perspective in an effort to provide a mechanistic framework for the  
dose-dependent  paradoxical  effects  of  estrogens  in  stroke.  It  is  concluded  that  five 
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protective  mechanisms,  namely  decreased  apoptosis,  growth  factor  regulation,  vascular 
modulation, indirect antioxidant properties and decreased inflammation, and the proposed 
damaging mechanism of increased inflammation, are currently supported by experiments 
performed in optimal biological settings. 
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List of Abbreviations 
ACh   Acetylcholine 
AMPA   α-Amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
Apaf-1   Apoptotic Protein-Activating Factor-1 
BDNF   Brain-Derived Neurotrophic Factor 
BH3   Bcl Homology domain-3 
CA1   Cornu Ammonis area-1 
cAMP  Cyclic Adenosine Monophosphate 
cGMP   Cyclic Guanosine Monophosphate 
COX   Cyclooxygenase 
CREB   cAMP Response Element Binding protein 
eNOS   Extracellular Nitric Oxide Synthase 
ER   Estrogen Receptor 
ERE   Estrogen Response Elements 
ERK   Extracellular signal-Regulated Kinases 
GABA   Gamma-Aminobutyric Acid 
GAP-43   Growth-Associated Protein-43 
GPR-30   G-Protein coupled Receptor-30 
GSK-3β  Glycogen synthase kinase 3β 
IGF-I   Insulin-like Growth Factor-I 
IL   Interleukin  
iNOS   Inducible Nitric Oxide Synthase 
IRA   Innovative Research of America 
LPS   Lipopolysaccharide  
LTP   Long Term Potentiation 
MAPK   Mitogen-Activated Protein Kinase 
MCAo   Middle Cerebral Artery Occlusion 
MPO   Myeloperoxidase 
NADPH   Reduced form of Nicotinamide Adenine Dinucleotide Phosphate 
NFKB   Nuclear Factor Kappa-light-chain-enhancer of activated B cells 
NGF   Nerve Growth Factor 
NMDA   N-Methyl-D-Aspartate 
nNOS  Neuronal Nitric Oxide Synthase Int. J. Mol. Sci. 2011, 12               
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NO   Nitric Oxide 
NT-4   Neurotrophin-4 
PGE2   Prostaglandin E2 
PI3   Phosphatidylinositol-3 
PUMA   p53-Upregulated Modulator of Apoptosis 
ROS   Reactive Oxygen Species 
SOD   Superoxide Dismutase 
Sp1   Specificity Protein-1 
STAT3   Signal Transducer and Activator of Transcription 3 
SVZ  Subventricular Zone 
TGF-α   Transforming Growth Factor-α 
TLR   Toll-Like Receptor 
TNF-α   Tumor Necrosis Factor-α 
VEGF   Vascular Endothelial Growth Factor 
1. Introduction 
In the 1990s, several studies demonstrated neuroprotective effects of estrogens in animal models of 
cerebral ischemia [1–3]. This supported a hypothesis of estrogen neuroprotection that earlier had been 
postulated from the clinical observation that women are less likely to suffer from stroke compared to 
men,  and  that  this  protection  diminishes  by  the  advent  of  menopause [4].  Several  previous 
epidemiological studies had also corroborated this hypothesis by indicating decreased stroke incidence 
in women on hormone replacement therapy [4]. Encouraged by the potential of estrogens as a mean of 
preventing illnesses including stroke and other cardiovascular diseases, substantial research efforts 
have been invested in further studies of the matter. However, later studies have been contradictory 
regarding estrogens’ effects on stroke, exemplified by the large randomized controlled trial Women’s 
Health Initiative, which was interrupted prematurely because of increased incidences of breast cancer, 
stroke  and  cardiovascular  disease,  thus  apparently  antagonizing  the  hypothesis  that  estrogens  are 
neuroprotective (it requires mention that in the case of this study conjugated equine estrogens were 
used, and not 17β-estradiol that has been used in most animal trials) [5].  
A few animal studies also reported increased ischemic damage from estrogens [6–11], in contrast to 
a  large  number  of  experiments  in  which  neuroprotection  was  found  [12–14].  This  dichotomy 
concerning  estrogens’  effects  in  animal  models  of  cerebral  ischemia  was  analyzed  in  a  recent 
systematic review of rat studies, designating the dose and mode of estrogen administration as the 
culprits [15], which was later experimentally confirmed [16]. Slow-release pellets for subcutaneous 
implantation produced by the company IRA (all abbreviations are listed above) was identified as the 
only mode of estrogen administration which has led to increased ischemic lesions, plausibly due to the 
prolonged,  supra-physiological  plasma  concentration  peak  (300–600  pg/mL,  in  comparison  to  the 
physiological  5–65  pg/mL)  which  characterizes  these  implants  [17].  This  is  well  in  line  with  the 
concept of hormesis, stating that steroid hormones can have diametrically different actions in different 
concentration  ranges [18].  The  fact  that  estrogens  seem  to  exert  their  effects  via  several  different 
pathways, such as the  classical nuclear receptors ER-α  and ER-β, membrane-linked receptors and Int. J. Mol. Sci. 2011, 12               
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through  direct  molecular  mechanisms  further  adds  to  the  complexity,  and  could  account  for  the 
hormesis phenomenon. The highest dosed pellets were in the abovementioned systematic review found 
to be most neurodamaging, while pellets containing lower doses of estrogens were more likely to be 
protective.  The  two  other  main  methods  of  administering  estrogens  to  rats;  subcutaneous  silastic 
capsules (generated serum concentrations of 40 pg/mL diminishing to 5 pg/mL in 42 days [17]) and 
subcutaneous  injections  (generated  baseline  17β-estradiol  concentrations  of  10–110  pg/mL [17]), 
showed consistent neuroprotection in the doses tested (Table 1) [15].  
Table  1.  Administration  method  dose  ranges  in  relation  to  neuroprotection  and 
neurodamage.  17β-estradiol  doses  and  capsule  concentration  ranges  reported  to  induce 
neuroprotection and neurodamage, respectively, in rat models of cerebral ischemia. For 
injection  regimens,  daily  doses  are  presented.  Silastic  capsules  containing  crystallized 
estrogen are omitted from the table, but were consistently neuroprotective [15]. 
Administration method 
Pellet dose/silastic capsule concentration/injection 
dose ranges 
  Neuroprotection  Neurodamage 
Slow-release pellets, subcutaneous  0.025–0.25 mg [19,20]  0.025–1.5 mg [6,8] 
Silastic capsules filled with 17β-estradiol 
dissolved in oil, subcutaneous 
180–4000 µg/mL [21,22]  Not reported 
Injections, subcutaneous  10–5000 µg/kg BW [23,24]   Not reported 
Injection, intravenous  10–1000 µg/kg BW [2,25]  Not reported 
Injection, intraperitoneal  100–20,000 µg/kg BW [26,27]  Not reported 
Injection, intramuscular  100 µg/kg BW [28]  Not reported 
Infusion, intraventricular  50–150 µg [29,30]  Not reported 
Oral administration  10 µg/kg BW [31]  Not reported 
Concerning  mechanisms  of  estrogens’  effects  in  cerebral  ischemia,  there  have  been  numerous 
explanations, mainly focusing on estrogens’ protective properties, but also with some suggestions of 
detrimental pathways. In the following sections, we will review the five most extensively investigated 
potential  neuroprotective  mechanisms,  namely  decreased  oxidative  stress  (Section  2.1)  decreased 
inflammation  (2.2),  decreased  apoptosis  (2.4),  growth  factor  regulation  (2.5)  and  vascular  
modulation (2.6), and the three suggested neurodamaging mechanisms increased oxidative stress (2.1), 
increased  inflammation  (2.2)  and  increased  excitotoxicity  (2.3).  Each  section  consists  of  a  brief 
summary of data supporting the mechanism hypothesis, when required also with a complementary 
description  of  pathways.  Subsequently  the  estrogen  administration  methods  used  and  in  the  cited 
studies are described, and it is discussed how well this matches with the notion that estrogens are 
protective  in  physiological  doses  and  damaging  in  very  high  doses.  Concerning  the  actual  serum 
estrogen concentrations in the cited studies, it is unfortunately very uncommon that researchers do 
measurements  of  17β-estradiol  on  more  than  one  occasion  during  an  experiment.  Concentrations 
measured in a single blood sample provide very little information about the serum concentrations at the 
other  time-points  of  the  study.  Therefore,  presenting  the  (in  the  vast  majority  of  cases)  single 
measurements from the studies cited run the risk of misleading the reader and is therefore not done 
here.  Further,  analysis  of  minute  amounts  of  17β-estradiol,  most  often  performed  with Int. J. Mol. Sci. 2011, 12               
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radioimmunoassay,  should—because  of  the  difficulties  in  calibrating  the  methods  and  the  large  
inter-assay  variations—always  be  performed  including  serum  from  native,  cycling  female  rats  to 
obtain reference intervals, which sadly is even rarer [32]. However, it is important to bear in mind that 
even if blood levels are monitored, these only represent a crude estimate of the concentrations in the 
brain, where the actual effects take place. 
In  vitro  experiments  are  cited  throughout  the  review,  although  it  should  be  noted  that  the 
concentrations of estrogens used are generally several orders of magnitude higher than in whole-animal 
experiments and therefore hard to interpret to in vivo conditions. Interestingly, the dose-dependent 
dichotomy of studies reporting protective versus damaging results found in whole-animal experiments 
is not found in cell culture experiments. 
Figure 1. A simplified map of suggested pathways and mechanisms for estrogens’ effects 
in stroke. Orange and blue rectangles mark plausibly detrimental and protective effects, 
respectively.  The  balance  in  the  background  symbolizes  that  depending  on  the 
circumstances,  such  as  the  dose  of  estrogen,  either  the  protective  or  detrimental 
mechanisms may dominate. The ―E‖ in the middle of the figure is short for ―Estrogens‖ 
(other  abbreviations  are  detailed  above  the  Introduction).  Depicted  pathways  and 
mechanisms have previously been reviewed in numerous publications [12,13,34,37–43]. 
Each part of the figure is matched with exact citations in respective sections throughout  
the article. 
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Although  not  reviewed  below,  a  number  of  additional  suggested  protective  mechanisms  also 
deserve  mention,  even  though  research  efforts  into  their  pathways  are  still  in  early  stages.  These 
include increased recruitment of stem cells from the subventricular zone [33], avoidance of apoptosis 
by balancing phosphatase activity [34] and decrease of excitotoxicity by reducing NMDA-signaling 
(please note that the opposite; that estrogens may increase excitotoxicity and thereby increase ischemic 
damage, is reviewed under 2.3) [35,36]. A simplified map of pathways and actions of estrogens that 
have been postulated to influence cerebral ischemia in a protective or detrimental direction is presented 
in Figure 1. 
2. Mechanisms for Estrogens’ Neuroprotective and Neurodamaging Effects 
2.1.  Decreased  and  Increased  Oxidative  Stress  as  Mechanisms  of  Estrogen  Neuroprotection  
and Neurodamage 
Oxidative stress is an important mechanism in cellular damage in general and cerebral ischemia in 
particular. Ischemia prompts mitochondria to produce ROS, which causes direct damaging oxidative 
reactions such as lipid peroxidations, as well as triggering apoptotic cascades. The cell has intricate 
defense  systems  against  oxidative  damage,  including  scavenging  activity  by  SOD,  glutathione 
peroxidase, and catalase, and further detoxification by small molecules such as glutathione, ascorbic 
acid, and α-tocopherol. However, during cerebral ischemia, especially reperfusion, these systems are 
generally overrun by the massive oxidative stress [44]. Estrogens have been stipulated to exert their 
neuroprotective effects  both  through direct  chemical  effects and  indirectly via upregulation of the 
cell’s anti-oxidative defense mechanisms (Figure 1) [34].  
2.1.1. Direct Anti-Oxidative Effects 
Direct anti-oxidative effects have been found in several studies. More specifically, estrogens have 
been  reported  to  prevent  intracellular  peroxide  accumulation  in  an  ER-independent  manner  [45], 
decrease  ROS  production  [46],  limit  lipid  peroxidation  [47–50],  protect  against  oxidative  stress  
FeSO4 [51], and to decrease hydrogen peroxide concentrations [30]. In one of these studies, no extra 
protection was afforded by adding known potent free radical scavengers, indicating that estrogens 
exert  all  the  protective  effects  available  through  anti-oxidative  mechanisms [48].  Further,  
17α-estradiol,  a  less  feminizing  enantiomer  of  17β-estradiol,  has  been  shown  to  protect  against 
glutamate and hydrogen peroxide stress to a similar extent as 17β-estradiol, indicating the importance 
of receptor-independent pathways [52]. Anti-oxidative mechanisms have also been suggested merely 
on the basis that estrogens can protect against oxidative stress, although it should be emphasized that 
protection  against  an  oxidative  assault  is  not  necessarily  dependent  on  a  primary  anti-oxidative 
mechanism [53,54]. A further mechanism for estrogens’ direct anti-oxidative effect was proposed by 
Prokai et al., providing evidence that estrogens can engage in a redox cycle in which estrogens turn 
into a quinol when eliminating a radical, to subsequently be converted back to the parent estrogen 
using NADPH as a reducing agent [55,56]. Interestingly, it was demonstrated that the quinol-cycling 
actually  made  the  compound  function  as  a  prodrug  that  was  selectively  activated  in  the  brain, 
importantly  without  uterotropic  actions [55].  17β-estradiol’s  anti-oxidative  effect  has  also  been Int. J. Mol. Sci. 2011, 12               
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attributed to the hydroxyl group in the C3 position of the A ring, even though one study found no 
protection by neither of 2-hydroxyestradiol nor 2-methoxyestradiol, despite the fact that these estrogen 
metabolites have intact hydroxyl groups [57]. However, the last-mentioned study is difficult to assess 
because of possible differences in brain-uptake by the three compared compounds, and further, in 
another article it is on the contrary reported that 2-methoxyestradiol protects against ischemia [58]. 
Taken  together,  the  current  evidence  indicates  that  estrogens  exert  direct  anti-oxidative  effects 
under certain circumstances. However, it requires emphasis that the genomic and non-genomic actions 
of estrogens are impossible to firmly separate, especially in vivo. Also, an important concern is that the 
abovementioned studies mainly have been performed in vitro and using hormone concentrations that 
are  extremely  high (in the magnitude of 0.1–100 µM) compared to what is normally achieved in 
animal  models  of  cerebral  ischemia [15,45,46,49,50].  An  exception,  which  seems  to  support  the  
anti-oxidative evidence, is a study by Kii et al., in which estrogens were shown to decrease levels of 
hydrogen peroxide measured by microdialysis, which were not decreased by tamoxifen in a rat model 
of cerebral ischemia [30]. However, the results of this study remain to be confirmed in studies less 
fraught with assessment difficulties. Since estrogens are protective in cerebral ischemia only within a 
relatively  narrow  and  low  range  of  concentrations,  studies  showing  the  part  played  by  estrogens  
anti-oxidative  effects  in  physiological  concentrations  in  vivo  remain  to  be  done.  Thus,  although 
estrogens are likely neurodamaging in high concentrations, even much higher levels, only relevant in 
cell cultures, seem to be required to produce the direct anti-oxidative effects of estrogens. 
2.1.2. Indirect Anti-Oxidative Effects 
Indirect anti-oxidative effects of estrogens have been reported including attenuation of microglial 
superoxide  release  [59],  increase  of  glutathione  reductase,  gamma-glutamylcystein  synthetase, 
glutaredoxin  and  glutathione  [60–64],  increased  MnSOD  activity  [65,66]  and  expression  [67,68], 
upregulation  of  Cu/Zn  SOD  expression  [67],  reduction  of  free  radical  production  via  an  increase 
mitochondrial efficiency [69,70], attenuation of NADPH oxidase activation [71,72] and decrease of the 
oxidative stress marker nitrotyrosine [67]. These effects have been found to at least in part result from 
nuclear ER-mediated upregulation of anti-oxidative proteins [34]. 
In contrast to the direct anti-oxidative mechanisms presented in the above section, these examples 
of upregulation of the oxidative defense system has been demonstrated in many studies in relevant 
biological  contexts,  such  as  mice  and  rats  receiving  subcutaneous  and  intraperitoneal  
injections [64,67,69–71]. Thus, at present the proposed indirect anti-oxidative mechanisms seem more 
likely to be relevant in actual whole-animal cerebral ischemia models than the direct anti-oxidative 
mechanisms do. 
2.1.3. Pro-Oxidative Effects 
As  aforementioned,  estrogens  have  also  been  shown  to  increase  oxidative  stress,  and  thereby 
possibly  augment  ischemic  damage  (Figure  1) [9,73].  The  reported  pro-oxidative  effects  include 
increased  mitochondrial  ROS  production  [74,75],  oxidative  DNA-damage  in  sperm  and  ovarian 
surface  epithelium [76,77], reduced  levels of  anti-oxidant proteins in rat  brain  [78], promotion of 
oxidative damage in rat liver cells [79] and increased ROS-production from the estrogen metabolites  Int. J. Mol. Sci. 2011, 12               
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2-methoxyestradiol and 4-hydroxyestradiol [80–82]. However, these pro-oxidative effects of estrogens 
have mainly been reported from in vitro experiments and in other tissues than the brain, while studies 
on the nervous system almost uniformly have found estrogens to exert anti-oxidant properties [73]. 
This could possibly reflect tissue-specific estrogen response patterns,  which has been proposed to 
result from differences in cellular balance of ER-β versus ER-α [73]. 
Apart  from  a  study  by  Pajovic  et  al.  [78],  studies  demonstrating  pro-oxidative  properties  of 
estrogens in a biological context relevant to cerebral ischemia are lacking. In this study, levels of 
glutathione peroxidase, glutathione-S-transferase and glutathione reductase in male rat brains were 
decreased in response to moderately dosed exogenous estrogen. Theoretically, this decrease is likely to 
hamper the cells’ anti-oxidative defense, increasing the risk of ischemia-induced cellular damage [78]. 
Even taking this study into account, the evidence for estrogenic pro-oxidative actions as a mechanism 
for increased damage in cerebral ischemia appears scarce, and it cannot be included as a plausible 
pathway for estrogens’ damaging effects. 
2.2. Anti- and Pro-Inflammatory Actions as Mechanisms of Estrogen Neuroprotection and Neurodamage 
Cerebral ischemia triggers an acute and prolonged inflammatory process in the brain, characterized 
by  activation  of  microglia,  production  of  inflammatory  cytokines  and  infiltration  of  various 
inflammatory  cells,  including  neutrophils,  T-cells  and  monocytes/macrophages,  into  the  damaged 
tissue. The inflammatory process is considered an important component of the pathophysiology of 
stroke,  and especially  the early inflammatory  cell infiltration and cytokine production seem  to be 
predominantly deleterious [83]. Experiments in rats have shown that intraventricular administration of 
TNF-α, IL-1 and IL-6 exacerbates stroke damage, suggesting a detrimental role of inflammation in the 
ischemic process [84–86]. Further support for this hypothesis is found in the observation that blockage 
of pro-inflammatory cytokines ameliorates ischemic damage [86–91]. 
2.2.1. Anti-Inflammatory Effects 
Anti-inflammatory properties of estrogens have been demonstrated in a large number of studies, and 
are commonly taken as important mechanisms for estrogens’ neuroprotective effects in stroke [86]. 
Estrogens have been shown to induce a wide range of anti-inflammatory effects via, for example, 
reducing  leukocyte  adhesion [92–94],  decreasing  pro-inflammatory  cytokine  production  [95–102], 
decreasing  monocyte  activation  [103]  and  altering  the  microglial  activation  pattern  [104].  Both 
leukocytes and microglia express ER, offering a direct pathway for estrogens’ actions in inflammatory 
processes [86], and ER activation is e.g., thought to regulate iNOS transcription [105]. The classical 
pro-inflammatory cytokines IL-1, IL-6 and TNF-α lack ERE, but are thought to be affected by for 
example activated ER’s down regulation of nuclear c-Jun and JunD, leading to decreased occupation 
of AP-1 which in turn could increase the expression of TNF-α (Figure 1) [106]. 
The studies designed to investigate estrogens’ actions in inflammation have to a large extent been 
performed in cell cultures, where hormone concentrations are hard to extrapolate to concentrations in 
intact organisms. Of the studies performed in animals, most have focused on other organs than the 
brain, which potentially could lead to misinterpretation if the data are extrapolated to estrogens effects 
in cerebral ischemia. The effects of estrogens on inflammation are in many aspects organ specific, Int. J. Mol. Sci. 2011, 12               
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vividly exemplified by the estrogen-induced prostatitis in rats [107] in contrast to the amelioration of 
soft tissue inflammatory conditions [108]. To elucidate at which estrogen concentrations anti-inflammatory 
effects in the brain occur, we here narrow our focus to studies performed to assess effect on cerebral 
inflammation in animals. These are comparatively few, but include experiments that have shown that 
estrogens  limit  the  activity  of  the  pro-inflammatory  transcription  factor  NFKB  in  a  rat  MCAo  
model  [109],  decrease  leukocyte  adhesion  both  before  and  after  transient  forebrain  ischemia  in  
rats [92], reduce number of microglia and astrocytes in mice [110], decrease cytokine production in 
animal models of MCAo [96] and NMDA-induced toxicity [97], block COX-2 activity and PGE2 
production after IL-1β administration in rats [102], reduce iNOS activity [105], and decrease monocyte 
activation  and  recruitment  in  response  to  LPS  [103].  In  two  studies,  the  importance  of  
anti-inflammation  for  estrogens’  actions  have  been  demonstrated  by  the  lack  of  17β-estradiol 
neuroprotection  in  iNOS  knockout  mice [111]  and  mice  treated  with  the  iNOS  inhibitor 
aminoguanidine [112]. 
Of  these  studies,  all  but  two  have  adopted  presumptive  low-dose  or  short-term  17β-estradiol 
regimes,  such  as various intraperitoneal or  subcutaneous injection schedules and low-dose  silastic 
capsules,  which  are  in  the  dose  range  likely  to  induce  protection  against  ischemic 
damage [15,92,95,96,102,103,105,109–112]. The remaining two of the abovementioned studies used 
pellets from IRA, which are high-dose regimes capable of inducing either protection or damage in 
cerebral ischemia [97,110]. In one of the studies using pellets [110], 17β-estradiol merely decreased 
the number of astrocytes and microglia without relation to stroke, which could be interpreted as a 
degenerative as well as an anti-inflammatory effect. Further, in the other high-dose pellet study, older 
rats  given  the  same  treatment  showed  increased  cerebral  inflammation  [97].  Thus,  of  the  studies 
reporting estrogen-induced decreases in animal brain inflammation, a majority have been performed 
with  short-term  or  low-dose  estrogens  similar  to  regimens  that  previously  have  been  reported  to 
decrease cerebral ischemic damage, which is as expected if anti-inflammation is one of the actual 
protective mechanisms [15]. 
2.2.2. Pro-Inflammatory Effects 
Paradoxically,  one  of  the  suggested  mechanisms  for  estrogens’  ability  to  increase  damage  in 
cerebral  ischemia  is  the  hormones’  pro-inflammatory  capacity  [7,37].  In  several  rat  experiments, 
estrogens have been reported to potentiate leukocyte adhesion, increase P-selectin and MPO enzyme 
activity  in  cerebral  ischemia  [7,113],  increase  TNF-α,  TLR-2  and  IL-12  in  response  to  LPS  
stress [114,115], increase IL-1β in a NMDA-toxicity model [97] and to worsen functional outcome in 
a model of chronic cerebral inflammation (Figure 1) [116]. 
Most interestingly, in sharp contrast to the majority of studies reporting decreased inflammation, all 
but  one  [113]  of  these  studies  adopted  administration  regimens  that  are  likely  to  produce  highly 
supraphysiological  17β-estradiol  concentrations  in  the  range  that  have  been  shown  to  exacerbate 
ischemic  damage  in  rats  [15,17].  The  high-dose  regimens  used  were  slow-release  capsules  
from IRA [7,97,115] and silastic capsules containing dissolved 17β-estradiol in concentrations about 
10  [114]  to  250  [116]  times  higher  than  the  highest  dissolved  silastic  capsule  17β-estradiol 
concentration that, to the best of our knowledge, has been reported to be neuroprotective [117]. The Int. J. Mol. Sci. 2011, 12               
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pro-inflammatory effects of estrogens have generally not been interpreted as resulting from the high 
hormone dose, but rather as synergistic effects of diabetes [7,113] and old age [97,115,118]. However, 
a possible contribution of factors such as age and disease do not explain the striking dominance of 
high-dose  regimens  in  these  experiments,  thereby  suggesting  that  estrogens  in  supraphysiological 
concentrations  are  likely  to  have  a  higher  propensity  for  increasing  inflammation,  supporting  the 
hypothesis  that  high-dose  estrogens  increase  damage  from  cerebral  ischemia.  It  should  also  be 
mentioned that estrogens indeed have been reported to protect both diabetic and old animals in several 
studies,  contradicting  a  clear  relation  between  age,  diabetes  and  neurodamaging  effects  of  
estrogens [119–123]. 
2.3. Increased Excitotoxicity as a Mechanism of Estrogen Neurodamage 
Excitotoxicity  is  a  well-established  feature  in  cerebral  ischemia,  and  contributes  to  the 
pathophysiology  by  a  series  of  events  characterized  by  abnormal  excitation  by  neurons  due  to 
pathological release of excitatory neurotransmitters from damaged cells. In the process, both NMDA 
and AMPA glutamate receptors are over stimulated, contributing to uptake of Na
+, Cl
− and Ca
2+ ions, 
which depolarizes neurons and leads to subsequent transmitter release, further stimulating receptors in 
a  vicious  cycle.  The  ion  uptake  leads  to  cellular  edema  and  to  activation  of  various  detrimental  
Ca
2+-dependent enzymes, which in turn damage the cell by degrading cytoskeletal proteins, damaging 
DNA and by increasing the generation of free radicals [124]. 
It has been stipulated that estrogens could augment the pathological process in cerebral ischemia by 
potentiating the excitotoxicity since estrogens have been reported to increase NMDA mRNA in the 
hippocampal CA1-region [125], increase NMDA-binding sites in CA1 [126,127], increase dendritic 
spine density or decreased ovariectomy-induced dendritic spine loss in CA1 [126,128–130], increased 
sensitivity of CA1 pyramidal cells to NMDA receptor-mediated synaptic input [126], facilitate seizure 
activity  [131],  augment  LTP  [132,133],  increase  the  excitability  of  different  neurons  [134,135], 
decrease  glutamate-uptake  by  astrocytes  [136]  and  to  facilitate  kainite  induced  currents  via  
cAMP-dependant phosphorylation (Figure 1) [137]. It is likely that a substance that facilitates NMDA 
activity and increases excitability could potentiate excitotoxicity and augment ischemic damage. In 
line with this hypothesis, it has been reported in several articles that decreased excitotoxicity, either by 
reducing the number of collaterals [138–140] or potentiating GABA-ergic transmission [141,142], is 
associated with amelioration of ischemic damage. 
However, of the many aforementioned studies performed on animals, the vast majority have seen 
the potentially excitatory effects from low-dose or short-time estrogen administration regimens that are 
likely to protect from rather than increase ischemic damage [15,17,126,127,129,132,135]. None of the 
studies adopted the high-dose pellets from IRA that have been shown to be detrimental in cerebral 
ischemia. Thus it is as yet not established whether estrogens are able to increase excitotoxicity in doses 
that are relevant to the animal models that have reported increased ischemic damage from estrogens. 
Also, the abovementioned studies have merely presented indirect evidence of increased excitotoxicity 
by estrogens. In contrast, several studies have shown decreased excitotoxicity from estrogens in the 
same  dose  range  (Figure  1) [36,143–149].  The  studies  indicating  estrogen-induced  increased Int. J. Mol. Sci. 2011, 12               
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excitotoxicity have notably largely been restricted to hippocampus, while the ischemic damage in the 
most common animal stroke model (MCAo) primarily involve the striatum and cerebral cortex. 
In  conclusion,  the  hypothesis  that  estrogens  exacerbate  ischemic  damage  by  potentiating 
excitotoxicity  has  limited  support  since  (1)  the  potentially  excitotoxicity-increasing  effects  have 
mainly been demonstrated in experimental paradigms involving presumably neuroprotective hormone 
regimens; (2) no direct evidence of increased excitotoxicity is as yet available; (3) several studies have 
reported direct signs of decreased excitotoxicity from estrogen treatment; and (4) the studies reporting 
excitatory effects have largely been restricted to hippocampus, possibly reflecting site-specific effects.  
2.4. Decreased Apoptosis as a Mechanism of Estrogen Neuroprotection 
Apoptosis is a major pathophysiological mode of cell death in ischemic brain injury [150,151]. 
Ischemia triggers mitochondria to produce reactive oxygen species, which do not only directly damage 
lipids, proteins and nucleic acids in the cell, but also activate various intracellular pathways that return 
to the mitochondria to induce apoptotic cell death, in part through regulation of pro- and antiapoptotic 
proteins such as the Bcl-2 family [151]. The Bcl-2 family is an essential group of proteins that regulate 
the  integrity  of  the  mitochondrial  membrane,  and  is  subdivided  into  three  subgroups  based  on 
structural homology: antiapoptotic proteins including Bcl-2, Bcl-XL and Bcl-w; proapoptotic proteins 
such as Bax and Bak and the BH3-only proteins including Bad, Bim, Noxa and PUMA [151]. An 
overweight of pro-apoptotic proteins at the membrane triggers the release of cytochrome c into the 
cytosol, which in turn combines with Apaf-1 and procaspase-9 to activate various caspases, such as 
caspase-3. The caspases are the proteins that perform the cellular degradation in apoptosis, exemplified 
by caspase-3’s cleavage of DNA repair enzymes leading to DNA damage [152]. Another feature of 
apoptotic cell death is the seemingly mandatory increase in expression of the so-called immediate early 
genes, such as c-Jun and c-Fos [153,154], which can be used as markers of apoptosis [155]. The 
importance of apoptosis in stroke is suggested by the neuroprotection afforded by increased expression 
of the antiapoptotic Bcl-2 [156,157] and by the ischemia-induced upregulation of proapoptotic proteins 
in animal models of cerebral ischemia [158].  
Estrogens have been reported to reduce apoptosis in a number of studies. The antiapoptotic effects 
of estrogens include blocking the ischemia-induced reduction of Bcl-2 following MCAo [157,159], 
reducing caspase-3 after global ischemia [160], increasing expression of Bcl-2, Bcl-w and Bcl-XL 
while decreasing Bax, Bad and Bim [161–167], attenuating injury-mediated DNA fragmentation [21], 
reducing the level of the 120 kDa caspase-mediated spectrin breakdown product [21], decreasing c-Fos 
induction  [155],  limiting  apoptosis  induced  by  staurosporine  in  cell  cultures  [168],  inducing  
cGMP-dependent  expression  of  thioredoxin—a  redox  protein  with  potent  antioxidative  and 
antiapoptotic properties [169]—and preventing glutamate-induced translocation of cytochrome c from 
mitochondria to  cytosol (Figure 1) [170].  ER  activation  is  also thought to limit  apoptosis through 
increased expression of components in oxidative phosphorylation, making energy production more 
stable and thus maintaining mitochondrial membrane integrity [34]. Further, Bcl-2 over-expressing 
male mice sustained smaller infarct sizes compared to their male wild type counterparts, while this 
difference  was  not  observed  in  females,  which  is  likely  to  mean  that  apoptosis  is  one  of  the 
mechanisms of estrogen neuroprotection [157]. Int. J. Mol. Sci. 2011, 12               
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Considering the potential pathways for estrogens’ antiapoptotic actions, it is of interest that the  
Bcl-2 gene promotor has no ideal consensus sequence for an ERE, but that estrogens can interact with 
Sp1 for which there are several binding sites in the Bcl-2 gene promoter [171]. Also, estrogens have 
been shown to induce Bcl-2 expression through STAT3 and phosphoinositide-3-kinase/Akt-dependent 
CREB, which in turn possibly is activated by GPR-30 [164,168,172]. Akt also targets procaspase-9, 
members  of  the  Forkhead  family  of  transcription  factors,  which  promote  pro-death  gene  
transcription [41]. These increases in antiapoptotic factors compared to proapoptotic factors afforded 
by  estrogens  are  generally  considered  to  convey  neuroprotection  by  preventing  activation  of  the 
permeability  transition  pore,  thereby  protecting  against  a  cytosolic  Ca
2+-overload  and  release  of 
cytochrome c into the cytosol [42,173].  
Many of the aforementioned studies have been performed in animal models catering for in vivo 
relevant dose intervals in which the mechanism occurs. The reported antiapoptotic effects of estrogens 
presented above have been demonstrated using several different hormone administration protocols, though 
with an overwhelming dominance of low-dose and/or short-term regimens [15,17,21,155,159,165,166]. 
This corroborates the combined hypotheses that estrogens are neuroprotective through antiapoptotic 
mechanisms and that neuroprotection due to estrogens are mainly seen in low dose and/or short-term 
hormone  regimens.  However,  to  our  knowledge  no  study  has  been  performed  where  estrogens’ 
influence on apoptosis has been inhibited, and where the effect of such an inhibition has been assessed. 
2.5. Growth Factor Regulation as a Mechanism of Estrogen Neuroprotection 
Estrogens are known to regulate growth factors, an attribute that has been suggested as another 
mechanism  for  the  hormones’  beneficial  effects  in  cerebral  ischemia  [12,41].  Growth  factors 
contribute to improved outcome after cerebral ischemia both by facilitating recovery and by decreasing 
apoptosis, thereby reducing infarct size [174]. This mechanism overlaps considerably with apoptosis, 
even if the extensive research focused on estrogens interaction with growth factors merits special 
attention. Also, the positive, possibly neuroprotective, effects of estrogens on neural cell proliferation, 
synaptogenesis, modulation of synaptic connectivity and regeneration [175,176] are probably mediated 
through regulation of growth factors and neurotrophins, including TGF-β, IGF-I, NGF, BDNF and 
NT-4 (Figure 1) [177–182]. 
17β-estradiol regulates the transcription of numerous growth factor genes through ERs’ binding to 
ERE in gene promoters. The factors influenced in this manner include, i.e., VEGF [183], TGF-α [184], 
tau [185], BDNF, NT-4 and NGF [41,179]. ER not only co-localizes with and regulates the expression 
of neurotrophins and their cognate receptors, but estrogens and neurotrophins also share converging 
signaling  pathways  in  the  MAPK  cascade,  which  includes  activation  of  B-Raf  and  ERK,  in  turn 
regulating  a  broad  array  of  cytoskeletal  and  growth-associated  genes  [186].  Additional  evidence 
implying  that  estrogens  exert  their  positive  effects  via  growth  factor  interaction  includes  the 
cooperation with IGF-I to exert neuroprotection, possibly by sharing the MAPK and PI3/Akt signaling 
pathways [177,187]. Interestingly, IGF-I receptor blockade prevents estrogen neuroprotection while 
the ER antagonist ICI 182,780 can block IGF-I neuroprotection [188,189]. Similar results have been 
seen  in  models  of  cerebral  ischemia  [41,190],  and  in  another  study,  a  combination  of  IGF-I  and  
17β-estradiol  did  not  add  any  extra  protection  against  ischemia  compared  to  the  two  substances Int. J. Mol. Sci. 2011, 12               
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administered separately [191], emphasizing to the relation between estrogens and growth factors as a 
protective mechanism in stroke. Moreover, estrogens have been postulated to promote recovery after 
stroke  by  directly  regulating  genes  required  for  growth,  such  as  tau  microtubule-associated  
protein  [185],  GAP-43,  [192],  structural  lipoproteins  such  as  apolipoprotein  E  [193],  and 
neurofilament proteins [194]. 
Thus, ample evidence exists for the notion that estrogens increase the activity of growth factors as a 
major mechanism for neuroprotection. As expected, the interactions of estrogens with growth factors 
have  been  demonstrated  in  vivo  resulting  from  predominantly  low-dose  or  short  term  estrogen 
administration regimens [15,17,178,180,181,187–189,192,194]. Thus there is good coherence between 
the biological environments in which the growth factor interactions have been shown and the notion 
that estrogens mainly are neuroprotective in physiological concentrations. 
2.6. Vascular Modulation as a Mechanism of Estrogen Neuroprotection 
The importance of vascular properties, such as vessel wall reactivity and contraction propensity, for 
the  development  of  stroke  is  self-evident.  Even  though  this  category  of  factors  may  seem  less 
important  in  animal  models  of  cerebral  ischemia  where  the  vessel  occlusion  is  artificial,  it  still 
influences the crucial aspects of collateral circulation and reperfusion. It is thus likely that increased 
vasodilatation in the cerebral vascular bed is beneficial in cerebral ischemia by facilitating blood flow 
to compromised brain regions [39]. The reactivity and contraction propensity of a blood vessel is 
strongly  influenced  by  locally  produced  vasodilators  including  prostacyclin  and  NO,  and 
vasoconstrictors such as endothelin-1, which in turn are regulated by other factors. 
Estrogens have been shown to affect cerebral blood vessels in a number of studies; by relaxing 
cerebral  arteries  through  inhibition  of  extracellular  Ca
2+  influx  in  vascular  smooth  muscle  [195], 
moderating  thrombotic  mechanisms  [196],  influencing  the  biosynthesis  of  prostacyclin  [197,198], 
potentiating  ACh-induced  endothelium-dependent  relaxation  [199],  enhancing  nNOS  and  eNOS  
levels [24,200–204] and thus increasing NO production [205–208], increasing COX-1 levels [200], 
and by less well characterized pathways which increase cerebral blood flow (Figure 1) [3,22,209–212]. 
It deserves mention that although eNOS could be neuroprotective through vasodilatation, it has also 
been  shown  to  induce  peroxynitrite  formation  under  certain  disease  states [213],  which  in  turn 
potentially  could  compromise  cellular  viability [214].  Most  of  these  effects,  such  as  influence  on 
eNOS, COX-1 and prostacyclin synthase leading to vasodilatation and improved collateral flow, seem 
to be exerted via the classical genomic pathway or via the PI3/Akt pathway [39]. 
Several of the effects of estrogens on the cerebral vasculature have been demonstrated in vivo using 
estrogen regimens that are in the dose-range likely to mediate neuroprotection [15], such as low-dose 
subcutaneous injections [24] or physiologically cycling hormones [209]. There are therefore strong 
indications  that estrogens  affect important  vessel properties in biological contexts relevant for the 
question of its effect on cerebral ischemia, even though evidence of this mechanism’s indispensability 
is lacking. Thus, to the best of our knowledge, no study has been performed where estrogens’ impact 
on blood vessels have been inhibited, and where the effect of such an inhibition has been assessed. 
Further, numerous studies have been unable to corroborate vascular effects of estrogens in stroke 
models,  notably  by  absence  of  blood  flow  differences  before  or  during  MCAo  between  estrogen Int. J. Mol. Sci. 2011, 12               
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treated  and  estrogen  deficient  animals,  even  though  differences  in  stroke  outcome  were  
observed [122,215–218]. 
3. Conclusions 
3.1. Quality of Mechanism Experiments 
Before an overall summary of the mechanisms dealt with here, brief considerations regarding study 
design, quality and causality may be in place.  
In the process of elucidating which mechanisms are important for a certain biological target effect 
exerted  by  an  investigated  substance,  different  studies  obviously  contribute  evidence  of  different 
weight, primarily depending on the experimental design. It is particularly difficult to draw conclusions 
about causality, exemplified by the fact that decreased/increased inflammatory response and oxidative 
stress resulting from estrogen supplementation may be a consequence of other mechanisms rather than 
a  primary  cause  of  the  decreased/increased  damage.  Studies  investigating  mechanisms  may  be 
allocated three alternative ranks according to increasing degree of evidence: 
1. The  lowest  degree  of  ―evidence‖  for  a  certain  mechanism  comes  from  the  discovery  of  a 
biological alteration, which potentially could bring about the biological target effect, in response 
to the investigated substance. An example is the finding that estrogens increase the concentration 
of the synaptic protein syntaxin, which hypothetically (without direct experimental evidence) 
could facilitate recovery after cerebral ischemia [219]. 
2. If the investigated substance has an effect on a presumed mechanism that in itself has been 
proven to exert the biological target effect the evidence is evidently stronger, even if the relative 
contribution  of  the  mechanism  cannot  be  quantified.  An  example  is  the  fact  that  estrogens 
upregulate  Bcl-2  [164],  a  protein  in  itself  proven  to  decrease  the  damage  from  cerebral  
ischemia [156,157]. 
3. A yet higher degree of evidence for a mechanism’s importance is afforded when the presence of 
a specific blockage inactivates the biological target effect. An example is estrogens’ lack of 
protective effects in iNOS knocked out mice [111]. 
Two  of  the  mechanisms  of  estrogens’  neuroprotection  are  supported  by  studies  of  the  highest 
evidence rank, providing the best evidence for causality between the mechanism and the outcome. 
These  are  the  abovementioned  importance  of  iNOS  [111,112]  and  the  indispensable  interactions 
between IGF-1 and estrogens [41,188–191]. Numerous studies in the current field do not reach the 
highest level of evidence, e.g., due to the lack of a suitable blocker, and thus the weight of the evidence 
in these studies needs to be adjusted accordingly. 
3.2. Summary of Mechanism Evaluations 
Decreased apoptosis, growth factor regulation, vascular modulation, indirect decrease of oxidative 
stress by altering the anti-oxidative defense and decreased inflammation have all been demonstrated in 
experimental settings fitting the dose-concentration range pattern established for neuroprotection and 
are thus likely candidates for being true protective mechanisms. Anti-inflammation (iNOS) [111,112], Int. J. Mol. Sci. 2011, 12               
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and  interaction  with  growth  factors  (IGF-I)  [41,188–191]  are  due  to  the  abovementioned  studies 
contributing with the highest evidence rank particularly well established. The direct anti-oxidative 
effect still needs to be demonstrated in relevant biological settings in estrogen concentration intervals 
known to be protective in whole-animal models, and this mechanism is, as aforementioned, especially 
difficult to assess because of the difficulties in separating genomic from non-genomic actions. 
Of the suggested neurodamaging counterparts, only increased inflammation has been reported to 
occur under biological settings imitating conditions under which estrogens have been shown to be 
detrimental in whole-animal stroke experiments, and is thus to date the only real candidate of being a 
true  damaging  mechanism.  The  pro-oxidative  effects,  with  their  inherent  problem  of  proving  
non-genomic  actions,  have  as  yet  mainly  been  demonstrated  in  non-neuronal  in  vitro  trials,  and 
increased excitotoxicity has even less experimental support.  
Thus while several mechanisms seem to contribute to the neuroprotective effects of estrogens in 
lower concentration ranges, it seems that possibly the anti-inflammatory effect of estrogens turning 
pro-inflammatory in supraphysiological concentrations could explain the observation that estrogens 
have  opposing  effects  in  different  concentrations.  It  should  however  be  emphasized  that  which 
mechanisms are true and false as assessed above is a highly complex issue, and that a review of this 
kind is better viewed as hypothesis-generating than hypothesis-testing. 
3.3. Difficulties in Studying the Complex Estrogenic Mechanisms 
When  reviewing  the  abundance  of  studies  investigating  possible  mechanisms  of  estrogens’ 
neuroprotective actions, risk of bias is evident in cases when different estrogen effects depending on its 
concentrations are not taken into account (relating to the concept of hormesis). Effects of estrogens 
assessed  as potentially  protective may sometimes just as well be interpreted as risks  of  increased 
damage. For example, in a study by Weiland, estrogens were found to increase NMDA binding sites in 
the hippocampus, which may be taken as a neurotropic effect (protective by facilitating recovery) or as 
a  risk  of  increased  excitotoxicity  (harmful  in  cerebral  ischemia)  [127].  In  another  study  estrogen 
replacement decreased the number of astrocytes and microglia in the hippocampus, which was taken as 
evidence for decreased inflammation instead of the possible alternative assessment that the estrogens 
induced neurodegeneration [110]. To minimize the risk of similar pitfalls, several controls are needed 
including e.g., the verification that the biological serum concentrations of estrogens are in the range 
proven to afford neuroprotection. Unfortunately, careful investigation of the administration methods 
used are scarce, and in the majority of instances when blood samples are drawn for analysis of serum 
estrogen levels the sampling is only performed at only one single time point (most often at animal 
sacrifice), which  thus  conveys  little information of the serum concentrations before and after  this 
specific moment. 
3.4. Final Remarks 
Investigations of different mechanisms for estrogens’ actions in stroke have been performed in a 
very wide range of concentrations, profoundly affecting the plausibility of the suggested mechanism 
given that the hormones’ neuroprotective and neurodamaging properties are in fact restricted to certain 
dose intervals. In future studies it is crucial that mechanisms are verified in relevant biological contexts Int. J. Mol. Sci. 2011, 12               
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where  special  care  has  been  taken  to  control  estrogen  concentrations.  This  in  combination  with 
experimental designs catering for the highest level of evidence will provide the solid ground needed 
for characterizing estrogens’ actions and pathways in cerebral ischemia. 
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